[Current data on tiagabine].
OBJECTIVE
To review current data regarding the mode of action, pharmacokinetics, clinical efficacy and tolerance of tiagabine (TGB).


METHODS
TGB is a drug which boosts gabergic inhibition by blocking the re-uptake of synaptic GABA by the glia and neurones. This specific mode of action leads to an antiepileptic effect in patients of all ages with partial seizures. The efficacy of TGB is complemented by good tolerance, especially when it is introduced slowly, over a period of eight weeks. This form of administration is also used with other new antiepileptic drugs, such as lamotrigine and topiramate. We consider the data regarding efficacy and tolerance found in the clinical trials and studies reported in the literature.


CONCLUSIONS
TGB is an effective, well-tolerated drug when used in patients with difficult-to-control partial crises. However, it should also be used in patients with less difficult-to-control seizures and in previously untreated patients so as to properly define its efficacy and tolerance.
Herranz
J L
JL
Servicio de Neuropediatría, Hospital Universitario Marqués de Valdecilla, Santander, España. med003087@nacom.es
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003577:Cytochrome P-450 Enzyme System / Q000187:drug effects; D004361:Drug Tolerance; D004827:Epilepsy / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D009557:Nipecotic Acids / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use*; D018079:Receptors, GABA / Q000187:drug effects; D000078308:Tiagabine
D000927:Anticonvulsants; D009557:Nipecotic Acids; D018079:Receptors, GABA; D003577:Cytochrome P-450 Enzyme System; D000078308:Tiagabine